Roots Analysis has done a detailed study on China Biopharmaceutical Contract Manufacturing Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 250+ page report, which features 100+ figures and 120+ tables, please visit this link

Key Market Insights
 Over 35 CMOs / CDMOs in China claim to offer a variety of services related to development and manufacturing of a wide range of biotherapeutic products
 Several players provide one-stop solutions and are capable of operating at various scales; the landscape includes a mix of both established players and new entrants
 In order to cater to the evolving needs of clients / sponsors, CMOs have established facilities across different regions of China; Eastern China, with the maximum number of sites, has emerged as a manufacturing hub
 With over 80 deals inked in past five years, there has been a surge in the partnership activity within this domain; majority of these collaborations were signed for the development and manufacturing of antibody-based products
 Big pharma players have also made significant investments in this region, including establishing new facilities, expanding existing R&D centers and growing manufacturing facilities, focused on biotherapeutics
 We expect global biopharmaceutical developers to continue to outsource their manufacturing operations to China in the long term; we anticipate the CMO industry in the region to grow at an annualized rate of ~13%, till 2030
For more information, please visit https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview

3.2. Overview of Biopharmaceuticals

3.3. Manufacturing of Biopharmaceuticals
3.3.1. Types of Expression Systems Used
3.3.1.1. Bacterial Expression Systems
3.3.1.2. Yeast Expression Systems
3.3.1.3. Insect Expression Systems
3.3.1.4. Plant Expression Systems
3.3.1.5. Mammalian Expression Systems
3.3.1.6. Fungal Expression Systems

3.3.2. Processing Steps
3.3.2.1. Upstream Processing
3.3.2.2. Downstream Processing

3.4. Overview of Contract Manufacturing
3.4.1. Contract Manufacturing Scenario in China
3.5. Need for Outsourcing in the Biopharmaceutical Industry
3.5.1. Biopharmaceutical Outsourcing in China: Regulatory Scenario

3.6. Commonly Outsourced Operations in the Biopharmaceutical Industry

3.7. Basic Guidelines for Selecting a CMO Partner
3.8. Advantages of Outsourcing Manufacturing Services
3.8.1. Benefits of Engaging Chinese Contract Service Providers

3.9. Risks and Challenges Associated with Biopharmaceutical Contract Manufacturing
3.9.1. Challenges Associated with Engaging Chinese Contract Service Providers
3.10. Future Perspective

4. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
4.1. Chapter Overview

4.2. Small Molecule and Large Molecule Drugs / Therapies
4.2.1. Comparison of Key Characteristics
4.2.2. Comparison of Manufacturing Processes
4.2.3. Comparison of Key Manufacturing-Related Challenges

5. COMPETITIVE LANDSCAPE
5.1. Chapter Overview

5.2. Chinese Biopharmaceutical Contract Manufacturers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Scale of Operation
5.2.4. Analysis by Location of Headquarters
5.2.5. Analysis by Location of Manufacturing Facilities
5.2.6. Analysis by Type of Product
5.2.7. Analysis by Types of Services Offered
5.2.8. Analysis by Type of Biologic
5.2.9. Analysis by Expression System Used
5.2.10. Analysis by Type of Bioreactor Used
5.2.11. Analysis by Mode of Operation of Bioreactor
5.2.12. Analysis by Packaging Form Used
5.2.13. Analysis by Regulatory Accreditations / Certifications

6. COMPANY PROFILES
6.1 Chapter Overview

6.2 ChemPartner Biologics
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Manufacturing Facilities and Capabilities
6.2.4. Recent Developments and Future Outlook

6.3. JHL Biotech
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Manufacturing Facilities and Capabilities
6.3.4. Recent Developments and Future Outlook

6.4. JOINN Biologics
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Manufacturing Facilities and Capabilities
6.4.4. Recent Developments and Future Outlook

6.5 MabPlex
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Manufacturing Facilities and Capabilities
6.5.4. Recent Developments and Future Outlook

6.6. Mycenax Biotech
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Manufacturing Facilities and Capabilities
6.6.4. Recent Developments and Future Outlook

6.7. WuXi AppTec
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Service Portfolio
6.7.4. Manufacturing Facilities and Capabilities
6.7.5. Recent Developments and Future Outlook

7. PARTNERSHIPS
7.1 Chapter Overview

7.2. Partnership Models

7.3. Chinese Biopharmaceutical Contract Manufacturers: Recent Partnerships
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Scale of Operation
7.3.4. Analysis by Type of Biologic
7.3.5. Analysis by Focus Area
7.3.6. Analysis by Therapeutic Area
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Geographical Analysis
7.3.9. Geographical Distribution by Number of Partnerships
7.3.10. Intercontinental and Intracontinental Agreements

8. RECENT EXPANSIONS
8.1. Chapter Overview

8.2. Chinese Biopharmaceutical Contract Manufacturers: Recent Expansions
8.2.1. Analysis by Year of Expansion
8.2.2. Analysis by Type of Expansion
8.2.3. Analysis by Scale of Operation
8.2.4. Analysis by Type of Biologic
8.2.5. Analysis by Location of Expansion Project
8.2.6. Analysis by Capacity of Expanded Facility
8.2.7. Most Active Players: Analysis by Number of Expansions
8.2.8. Analysis by Region

9. CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview

9.2. Scope and Methodology

9.3 Clinical Trial Analysis: Biologic Drugs
9.3.1. Analysis by Trial Registration Year
9.3.2. Analysis by Trial Phase
9.3.3. Analysis by Trial Status
9.3.4. Geographical Analysis by Number of Clinical Trials
9.3.5. Geographical Analysis by Enrolled Patient Population
9.3.6. Analysis of Enrolled Patient Population by Trial Registration Year
9.3.7. Analysis of Enrolled Patient Population by Trial Phase
9.3.8. Analysis by Type of Sponsor / Collaborator
9.3.9. Most Active Players: Analysis by Number of Registered Trials
9.3.10. Analysis by Clinical Trial Center
10. REGIONAL CAPABILITY ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Overall Landscape of Chinese Biopharmaceutical Contract Manufacturers
10.4. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Northern China
10.5. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Eastern China
10.6. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Central China
10.7. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Southern China

11. CAPACITY ANALYSIS
11.1. Chapter Overview

11.2. Assumptions and Methodology

11.3. Chinese Biopharmaceutical Contract Manufactures: Installed Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Scale of Operation
11.3.3. Analysis by Expression System Used
11.3.4. Analysis by Location of Manufacturing Facility
11.3.5. Analysis by Company Size and Location of Manufacturing Facility
11.3.6. Analysis by Company Size and Location of Manufacturing Facility

11.4. Concluding Remarks

12. BIG PHARMA BIOPHARMACEUTICAL MANUFACTURING INITIATIVES IN CHINA
12.1. Chapter Overview

12.2. List of Biopharmaceutical R&D and Manufacturing Initiatives of Big Pharma Players in China
12.2.1. Analysis by Number of Initiatives
12.2.2. Analysis by Year of Initiative
12.2.3. Analysis by Company and Year of Initiative

12.2.4. Analysis by Type of Initiative
12.2.5. Analysis by Type of Biologic

12.3. Competitive Benchmarking of Big Pharmaceutical Players
12.3.1. Harvey Ball Analysis: Big Pharma Investment Summary
12.3.2. Geographical Analysis by Investment Made

13. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
13.1. Chapter Overview
13.2. Assumptions and Key Parameters
13.3. Chines Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
13.4. Conclusion

14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview

14.2. Key Assumptions and Forecast Methodology
14.3. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030
14.3.1. Biopharmaceutical Contract Manufacturing Market in China for APIs, 2020-2030
14.3.2. Biopharmaceutical Contract Manufacturing Market in China for FDFs, 2020-2030

14.4. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Expression System Used
14.4.1. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Mammalian Systems
14.4.2. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Microbial Systems
14.4.3. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Other Expression Systems

14.5. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Scale of Operation
14.5.1. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Preclinical / Clinical Scale Operations
14.5.2. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Commercial Operations

14.6. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Size of Manufacturers
14.6.1. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Small Companies
14.6.2. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Mid-sized Companies
14.6.3. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Large and Very Large Companies

14.7. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Distribution by Type of Biologic
14.7.1. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Antibodies
14.7.2. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Vaccines
14.7.3. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Share of Other Biologics

15. COVID-19 Impact on China Biopharmaceutical CMO Market
15.1. Chapter Overview
15.2. Evaluation of Impact of COVID-19 Outbreak

15.2.1. Initiatives and Opinions of Key Players
15.2.1.1. WuXi AppTec

15.2.1.2. Boehringer Ingelheim
15.2.1.3. GE Healthcare
15.2.1.4. Lonza
15.2.1.5. AmbioPharm

15.2.2. Impact of China Biopharmaceutical Contract Manufacturing Market
15.3. Key Strategies to Adopt: A Bird’s Eye View
15.3.1. Immediate Steps
15.3.2. Short / Long-Term Steps

16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparison of SWOT Factors
16.7. Concluding Remarks

17. FUTURE OF THE CHINA BIOPHARMACEUTICAL CMO MARKET
17.1. Chapter Overview
17.2. Outsourcing Activities Anticipated to Increase in Future
17.3. Shift from One-time Contracts to Strategic Partnerships
17.4. Adoption of Innovative Technologies
17.4.1. Single Use Bioreactors
17.4.2. Novel Bioprocessing Techniques
17.4.3. Bioprocess Automation

17.5. Growing Popularity of the Quality by Design Principle in Bioprocessing
17.6. Increasing Focus on Niche Therapeutic Areas
17.7. Biosimilars Market to Contribute to Contract Service Revenues
17.8. Capability and Facility Expansions to Establish One Stop Shop Expertise
17.9. Increase in Financial In-flow and Outsourcing Budgets
17.10. Challenges Faced by Sponsors and Service Providers
17.10.1. Concerns Associated with Single Use Systems
17.10.2. Issues Related to Capacity Fluctuations

17.11. Concluding Remarks
18. INTERVIEW / SURVEY TRANSCRIPT(S)
19. APPENDIX 1: TABULATED DATA
20. APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]